The Effect of a Gamified Neuropathy Management Application on Cancer Behavior in Cancer Patients Undergoing Chemotherapy

The Effect of a Gamified Neuropathy Management Application on Cancer Behavior in Cancer Patients Undergoing Chemotherapy: A Prospective Follow-Up Study

This study will be conducted to determine the effect of a gamified neuropathy management application on cancer behavior in cancer patients undergoing chemotherapy.

Study Overview

• Status: Not yet recruiting
• Conditions: Cancer; Gamification; Nursing; Chemotherapy Induced Pain Neuropathy
• Intervention / Treatment: Behavioral: Gamified Neuropathy Management Application on Cancer Behavior

Detailed Description

Cancer patients may experience treatment-related issues throughout their treatment process. Chemotherapy-induced peripheral neuropathy is one of the symptoms that negatively affects patients' overall health status. Peripheral neuropathy can occur during or after chemotherapy, leading to sensory, motor, and autonomic nerve damage. It is particularly common among cancer patients receiving taxane- and platinum-based chemotherapy.

Effective management of neuropathy is a crucial aspect of nursing care. Here are some key points regarding this issue: pharmacological and non-pharmacological methods, lifestyle control, and nursing interventions are employed. The management of peripheral neuropathy can have a significant impact on the overall health and well-being of cancer patients undergoing chemotherapy. Nurses play a vital role in this process by providing support that enhances patients' quality of life and improves treatment outcomes.

Gamification applications, which have recently started to be used in patient education, represent a contemporary approach. However, no studies have been found utilizing gamification specifically in patient education for cancer. For this reason, this study aims to contribute to patients' neuropathy management using a gamification application.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: BETÜL ÇAKMAK, RN,PHD; Phone Number: 0534-082-92-87; Email: b.cakmak@aybu.tr

Study Locations

• Turkey
  • Ankara, Turkey, 06000
    • Ankara Yıldırım Beyazit University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Undergoing chemotherapy treatment and have completed their first cycle.
• Literate (able to read and write).
• Able to use a smartphone.
• Aged between 18 and 65 years.
• Willing to participate in the study voluntarily.

Exclusion Criteria:

• Participants who do not use the application during the study period
• Participants who fail to complete the data collection forms

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: control group; no intervention
Experimental: intervention group; Gamified Neuropathy Management Application	Behavioral: Gamified Neuropathy Management Application on Cancer Behavior; The study will be conducted in three phases: Phase 1: The content of the gamified neuropathy management application used in the study will be prepared by the researchers using relevant literature. Phase 2: The developed gamified neuropathy management application will be introduced to patients during one-on-one interviews at the daytime chemotherapy clinic. After collecting pre-test data, the application will be sent to the patients, who will be asked to use it for 8 weeks. Phase 3: Following the start of the study's implementation, patients will be contacted in the 4th and 8th weeks to collect mid-study and post-test data.; Other Names: intervention group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The effect of gamified neuropathy management application on chemotherapy-associated peripheral neuropathic pain.	DN4 Questionnaire: The DN4 pain questionnaire, developed by the French neuropathic pain group, is a questionnaire that includes symptoms and findings associated with neuropathic pain. The individual being evaluated answers the questions with yes or no. The total scale score is calculated by giving 1 point for each yes answer and 0 point for each no answer. In the scale, the cutoff value for neuropathic pain is determined as 4/10 and above. Turkish validity and reliability was determined by Unal-Çevik et al. It was made by and the Cronbach alpha coefficient was 0.97; The specificity and sensitivity in diagnosing neuropathic pain were found to be 96.6% and 95%, respectively.	6 months
The effect of gamified neuropathy management application on chemotherapy-associated peripheral neuropathic level	CIPNAT, Tofthagen et al. (2011b). CIPNAT, which is a Likert type scale, consists of 2 parts. The first part consists of 36 items asking about symptom frequency, severity, and discomfort. In the second part, there are 14 items that evaluate which of the daily living activities peripheral neuropathy affects. First, patients are asked whether any of the nine symptoms developed after chemotherapy treatment. The frequency, severity and discomfort of the symptoms experienced after each question answered "Yes" are scored and evaluated with a 0-10 numerical rating scale. If the answer to the first 4 questions on the scale is "No", the other questions are not continued. These questions are the questions that determine whether there is the presence of CBPN (Kutlutürkan et al. 2017). A high score from the scale indicates that CBPN is high. The Turkish validity and reliability study of the scale was conducted by Kutlutürkan et al. (2017). The Cronbach alpha coefficient of the scale is 0.970.	6 months
The effect of gamified neuropathy management application on cancer behaviour	Heitzmann et al. Developed by KSI-KV in 2011. This inventory is a 12-item unidimensional measurement tool designed to assess cancer patients' self-efficacy in coping. Each item of this 12-item scale is scored between 1-9. The scale score is calculated as the sum of all items. High scores from the scale indicate high self-efficacy for coping. The Cronbach alpha coefficient of this scale, which was evaluated on three sample groups, was found to be a = 0.84, a = 0.84, a = 0.88 for each sample, respectively. The construct validity of the scale was conducted using Exploratory Factor Analysis for the first sample, and four factors were obtained according to the results of the analysis: (1) Maintaining Independence and Positive Attitude; (2) Participating in Medical Care; (3) Coping and Stress Management; (4) Managing Affect. Adaptation of this scale to Turkish was made by İyigün et al. (2017).	6 months

Collaborators and Investigators

• Sponsor: Ankara Yildirim Beyazıt University

Study record dates

Study Major Dates

• Study Start (Estimated): January 1, 2025
• Primary Completion (Estimated): August 30, 2025
• Study Completion (Estimated): December 31, 2025

Study Registration Dates

• First Submitted: December 9, 2024
• First Submitted That Met QC Criteria: December 16, 2024
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: December 16, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: cancer; nursing; gamification; chemotherapy induced pain neuropathy
• Additional Relevant MeSH Terms: Nervous System Diseases; Neuromuscular Diseases; Peripheral Nervous System Diseases
• Other Study ID Numbers: 01.08.2024/78 KARAR NO:36

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: I have not discussed this with other researchers

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No